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D4.6 Aortoiliac Disease-Endovascular Treatment
For a detailed discussion of endovascular treatment of aortoiliac disease, see B 4 .3.2, Aortoiliac
PTA, p S98. Endovascular techniques such as PTA and stent placement have the advantage of
lower morbidity and mortality risk compared with open surgical revascularizations.l The death
and complication rates of aortoiliac PTA and stent placement were analyzed in a meta -analysis of
2,116 reported patients.Z Death within hospital stay (not 30-day mortality) averaged 0.14% for
PTA and 0.3% for stcnt procedures. The 30-day mortality rate averaged 0.8% for PTA and 1.0%
for stem procedures (For detailed discussion of complications of endovascular procedures, see B
4 .3.7, P Sl09). The mean systemic complication rate was 1.3%; the local complication rate,
9.6%; and the mean rate of major complications necessitating treatment was 4.3% for PTA and
5.2% for stents, respectively.- .
Endovascular procedures are generally performed on patients with less severe disease than those
undergoing surgical treatment. The risk tor endovascular technique is much lower than for sur-
gical treatment. However, PTA and stents offer a lower durability of the result as compared with
bifurcated graft surgery. The adjusted 4-year primary patency rate for treatment of eLI, with
technical failures included, was 53% after PTA and 67% after stent placement for the treatment
of stenoses.V Analysis of variables that could potentially affect the patency results shown some
hete rogeneity. However, disease severity (e LI vs claudication), lesion type (occlusion vs steno-
sis), and lesion site (common vs external iliac) were found to affect patency in some studies.4,5
An analysis of the results of the endovascular treatment of aortoiliac disease has already been
presented (see B 4.3.2, Aortoiliac PTA, p S98, and B 4.3.3, Aortoiliac Stents, p S101 ) and is
not repeated here. This is because these procedures have been predominantly performed for
claudication (proportion of patients undergoing procedures for claudication: 77% of PTA per-
formed for iliac stenoses, 82% of iliac PTA for occlusions, 78% of iliac stenting for stenosis, and
86% of iliac scenting for occlusion). It should therefore be pointed out, in reviewing these data
in comparison with the surgical bypass data presented earlier (see D 4.5.3, p S206), that the
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iliac PTA and stent data primarily reflect the treatment of unilateral (iliac) disease, with lesions
amenable to these modalities.
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D4.7 Introduction to Preferred Therapeutic Options
The decision about what type of revascularization to recommend ideally should be made by a
multidisciplinary team. Important issues that may influence the recommended decision are:
• lesion morphology
• risk of surgery for that particular patient
• previous procedures (ie, bypass or angioplasty)
• patient's life expectancy
• local expertise and experience with particular surgical or endovascular procedures
In general, endovascular procedures are safer and require shorter hospitalization compared with
surgical procedures. Durability of these endovascular procedures is, however, less well estab-
lished. For most lesions, there is no direct evidence comparing the results of endovascular or
surgical treatment in a controlled, prospective, randomized study.
The system used for preferred therapeutic options has been detailed (see B 4.3,
Endovascular Procedures for Intermittent Claudication, p 897). Lesions are defined and
then placed in four groups, each group usually being treated in a similar way. The two
extremes are type A lesions, in which endovascular approach is the treatment of choice,
and type D lesions, in which surgery is the treatment of choice. In between these two
groups are types B and C lesions, in which no firm recommendations can be made about
the preferred interventional option. However, endovascular treatment is more commonly
used in type B lesions and surgical treatment is more commonly used in type C lesions.
There is insufficient solid evidence to make any firm recommendations, particularly in the
case of types B and C. Most patients with CLI have multilevel disease, and it may be
appropriate to use different techniques for different lesions.
D 4.7.1 Aortoiliac Disease-Preferred Therapeutic Options
The following and other similarly set out recommendations merely consider tile probable rela-
tive merits of surgical and endovascular treatment, on the assumption that intervention is desir-
able. It is therefore identical to Recommendation 31 (p 598). The final choice of intervention,
particularly for category 2 and 3 lesions, will of course depend on a number of other considera-
tions, such as the patient's overall health, the severity of the local lesion, etc.
